FOLH1 and prostate cancer: In a prospective phase III trial of 764 intermediate- and high-risk prostate cancer patients with RP, the diagnostic sensitivity and specificity of 68Ga-PSMA-11 PET/CT for lymph node metastatic stage were 0.40 (95% CI: 0.34–0.46) and 0.95 (95% CI: 0.92–0.97), respectively [25].